Designed to provide real-time glucose readings for an industry-leading 15.5 days*†, Dexcom G7 15 Day will be available in the U.S. for people over the age of 18 with diabetes beginning on Dec. 1, 2025. Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers with full retail launch in the coming weeks. Dexcom CGM continues to be the most covered and reimbursed CGM brand on the market1. SAN DIEGO / Nov 20, 2025 / Business Wire / DexCom,... Read more
Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments Acquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier lives Exact Sciences' product lines feature advanced cancer screening and diagnostic... Read more
Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers.* Dexcom Smart Basal is FDA cleared and now the first and only CGM-integrated basal insulin dosing optimizer for adults aged 18 and older with Type 2 diabetes who are using long-acting insulin.1 SAN DIEGO / Nov 19, 2025 / Business Wire / DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today... Read more
Studies demonstrate Labcorp Plasma Detect MRD Technology can inform treatment strategies and advance cancer research BURLINGTON, N.C., Nov. 19, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced Labcorp Plasma Detect, a tumor-informed, blood-based assay used to detect molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was featured in two recent peer-reviewed... Read more
Cardiac Ablation Solutions growth of 71% on strength of pulsed field ablation (PFA) portfolio; Raising FY26 revenue and EPS guidance GALWAY, Ireland, Nov. 18, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its second quarter (Q2) of fiscal year 2026 (FY26), which ended October 24, 2025. Q2 Key Highlights Revenue of $9.0 billion, increased 6.6% as reported and 5.5% organic, 75 basis points... Read more
RANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the Conformité Européenne (CE) Marked BD Onclarity™ HPV Assay for the BD COR™ System and the BD Viper™ LT System have been accepted for the World Health Organization (WHO) list of prequalified in vitro diagnostic products, further expanding access to high-quality cervical cancer screening tools in low-... Read more
ROSA® Knee with OptimiZe™ Offers Personalized Surgical Planning and Drives Confidence in Delivering Accurate and Reproducible Outcomes1 WARSAW, Ind., Nov. 14, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of ROSA® Knee with OptimiZe™, an enhanced version of its ROSA® Knee System that offers a more customized experience... Read more
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood pressure and cholesterol Results demonstrate the advantages of WGS over WES and genotyping arrays for assessing genetic risk and identifying drug target candidates. SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- A study published today in Nature, authored by Illumina, Inc.... Read more
First-of-its-kind, automated system delivers increased sensitivity, specific identification of disease markers and improved laboratory workflow to support fast, confident diagnoses WALTHAM, Mass. / Nov 12, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced 510(k) clearance of the EXENT® Analyser and Immunoglobulin Isotypes (GAM) Assay**, a first-of-its-kind automated platform for clinical laboratories.... Read more
FRANKLIN LAKES, N.J., Nov. 12, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, introduces the PureWick™ Portable Collection System, a discreet, first-of-its-kind, battery-powered personal urine management device designed for wheelchair users to help improve mobility around and outside the home. The PureWick™ Portable Collection System builds on the success of the PureWick™ Urine Collection System,... Read more
Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders Full-year 2025 guidance maintained Ad Hoc Announcement Pursuant to Art. 53 LR GENEVA / Nov 11, 2025 / Business Wire... Read more
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed Sydney Mass Spectrometry is the first facility in the wider Asia Pacific region to offer Illumina Protein Prep, adding to a growing list of institutions revealing biological insights with exceptional clarity at scale Recent collaborations and projects including Genomics... Read more
Q4 revenue of $5.9 billion increased 8.3% as reported, 7.0% FXN and 3.9% organic Q4 GAAP and adjusted diluted EPS grew to $1.72 and $3.96, respectively FY25 revenue of $21.8 billion increased 8.2% as reported, 7.7% adjusted FXN and 2.9% organic FY25 GAAP EPS of $5.82 decreased 0.7%; adjusted diluted EPS of $14.40 grew 9.6% FY25 GAAP and adjusted gross margin up 20 basis points and 140 basis points, respectively, driven by BD Excellence FY25 GAAP operating margin... Read more
Raises Full Year Revenue and Margin Guidance ACTON, Mass. / Nov 06, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2025. Third Quarter Financial Highlights: Revenue of $706.3 million, increased 29.9%, or 28.2% in constant currency1, and exceeded the high end... Read more
SAN DIEGO, Nov. 5, 2025 /PRNewswire/ -- The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban on Illumina, Inc. (NASDAQ: ILMN), which had been in place since March 4, 2025. While the ban will be lifted on November 10, Illumina remains on the Unreliable Entities List (UEL), requiring government approval for instrument purchases. Illumina remains focused on achieving a positive resolution regarding its inclusion on the UEL and is committed... Read more
Total revenue from continuing operations increased 10%; constant currency organic revenue grew 9% As reported EPS from continuing operations increased to $1.94; adjusted EPS increased to $2.47 Fiscal 2026 constant currency organic revenue, EPS and free cash flow outlook increased DUBLIN, IRELAND , Nov. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 second quarter ended... Read more
Third quarter net sales of $2.001 billion increased 9.7% on a reported basis, 8.6% on a constant currency1 basis and 5.0% on an organic constant currency1 basis Third quarter diluted earnings per share were $1.16; adjusted1 diluted earnings per share were $1.90, an increase of 9.2% For full-year 2025, Company maintains reported revenue growth guidance, reflecting the latest currency expectations, and narrows constant currency1 and organic constant currency1 revenue... Read more
FRANKLIN LAKES, N.J., Nov. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective, multi-center study evaluating the Revello™ Vascular Covered Stent in patients with peripheral arterial disease (PAD). The announcement was made in conjunction with a late-breaking... Read more
FRANKLIN LAKES, N.J., Nov. 3, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Conformité Européenne (CE) marking in the European Union for its Enteric Bacterial Panel* (EBP) and Enteric Bacterial Panel plus* (EBP plus) for the BD COR™ System. By leveraging advanced Polymerase Chain Reaction (PCR)... Read more
IRVINE, Calif. / Oct 30, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights Q3 sales grew 14.7% to $1.55 billion, or 12.6% adjusted1, with strength across all product groups Q3 TAVR sales grew 12.4%; constant currency1 sales grew 10.6% Q3 TMTT sales of $145.2 million, growth driven by PASCAL and EVOQUE Q3 EPS of $0.502; adjusted1 EPS of $0.67 SAPIEN 3, which showed superiority... Read more
Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis GAAP operating margin of 21.0% and non-GAAP operating margin of 24.5% for Q3 2025 GAAP diluted EPS of $0.98 and non-GAAP diluted EPS of $1.34 for Q3 2025 Cash provided by operations of $284 million and free cash flow of $253 million for Q3 2025 Repurchased 1.2 million shares of our common stock for $120 million at an average price of $97.10 per share For... Read more
Portage, Michigan, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2025: Third Quarter Results Reported net sales increased 10.3% to $6.1 billion Organic net sales increased 9.5% Reported operating income margin of 18.7% Adjusted operating income margin(1) increased 90 bps to 25.6% Reported EPS increased 2.8% to $2.22 Adjusted EPS(1) increased 11.1% to $3.19 Third Quarter Net Sales Growth... Read more
Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0% Income from operations increased 15%; non-GAAP income from operations up 19% Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55 Operating cash flow of $457 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today... Read more
SAN DIEGO / Oct 30, 2025 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic1 basis. U.S. revenue grew 21% and international revenue grew 22% on a reported basis and 18% on an organic1 basis, all on a year-over-year basis. GAAP operating income... Read more
Third-quarter sales from continuing operations of $2.84 billion increased 5% on a reported basis and 2% on an operational basis1,2 Third-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.10); adjusted diluted EPS from continuing operations of $0.69 Andrew Hider joined the company as president and chief executive officer (CEO), now leading the company’s focus to drive continuous improvement and sustainable growth and create... Read more
Revenue increased 22% to $64 billion GAAP1 operating earnings increased 18% to $668 million; GAAP diluted EPS increased 11% to $1.88 Non-GAAP operating earnings increased 37% to $857 million, driven by segment profit growth across all five of the company's operating segments; non-GAAP diluted EPS increased 36% to $2.55 Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $9.65 to $9.85 and fiscal year 2026 non-GAAP adjusted free cash flow outlook to $3.0... Read more
Expected to be immediately accretive to Adjusted Earnings Per Share (EPS)¹ after close Attractive return profile given high growth and strong margin profile of Clario, and meaningful synergies - reflecting the company’s disciplined approach to capital deployment Further strengthens Thermo Fisher’s position as the trusted partner to pharma and biotech customers, delivering important customer benefits WALTHAM, Mass. / Oct 29, 2025 / Business Wire / Thermo Fisher... Read more
Symplicity blood pressure procedure is now covered for qualifying Medicare patients GALWAY, Ireland, Oct. 28, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has released the final National Coverage Determination (NCD) on renal denervation, applicable to the Symplicity Spyral™ renal denervation (RDN) system, also known as the Symplicity blood... Read more
Prioritized Regulatory Review Process in the U.S. Follows Japan PMDA Approval in September WARSAW, Ind., Oct. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's first-to-world iodine-treated total hip replacement system. This is the first product in Zimmer Biomet history to receive... Read more
Revenue of $4,100 million, up 5.2 percent year-over-year GAAP Net Income of $331 million, Adjusted EBITDA of $949 million GAAP Diluted Earnings per Share of $1.93, Adjusted Diluted Earnings per Share of $3.00 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.15x R&D Solutions contracted backlog of $32.4 billion, up 4.1 percent year-over-year Operating Cash Flow of $908 million; Free Cash Flow of $772 million, up 35 percent... Read more
Updates Full-Year Guidance Financial results from Operations for third quarter 2025 versus third quarter 2024: Revenue: $3.56 billion versus $3.28 billion Diluted EPS: $3.12 versus $2.00 Adjusted EPS: $4.18 versus $3.50 Updated Full-Year Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance: Revenue guidance of 7.4% to 8.0%; midpoint lowered 40 bps due to currency and acquisition timing Adjusted EPS range of $16.15 to $16.50; midpoint raised by... Read more
SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO / Oct 27, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately,... Read more
EXTON, Pa., Oct. 27, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the launch of its West Synchrony™ Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, Germany. This innovative system marks a significant shift in drug delivery solutions by offering a fully verified platform from a single supplier that will be commercially available... Read more
Long-term data shows significant and sustained blood pressure reductions in both office-based and 24-hour ambulatory blood pressure, reinforcing the durability, safety and effectiveness of the Symplicity™ blood pressure procedure in patients prescribed antihypertensive medications GALWAY, Ireland, Oct. 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term results from its final report of the SPYRAL... Read more
Labcorp plans to make Roche's Elecsys® pTau181 test available nationwide by early 2026 BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care... Read more
Delivered solid growth across Proprietary Products and Contract Manufacturing Segments Achieved double-digit growth in HVP Components Strengthened executive leadership team, including recently appointed CFO Robert McMahon Increases Full-Year 2025 Revenue and EPS Guidance EXTON, Pa., Oct. 23, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and... Read more
Highlights Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025. Net income for the quarter was $2.4 million or $0.03 per diluted share. Quarter three adjusted EBITDA was $396.7 million or 19.4% of revenue, representing an increase of 0.2% on quarter two 2025. Quarter three adjusted net income was $258.8 million or $3.31 per diluted ordinary share. Gross business wins in the quarter of $2,986 million, representing... Read more
FRANKLIN LAKES, N.J., Oct. 22, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new self-collection solution for HPV testing in markets outside the United States. This new innovation simplifies at-home sample collection for patients and further automates lab processing using high-tech robotics with the BD COR™ System. The new swab technology has been certified through the In Vitro Diagnostic... Read more
MARLBOROUGH, Mass., Oct. 22, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational1 basis and 15.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or $0.51 per share (EPS), compared... Read more
WALTHAM, Mass. / Oct 22, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 27, 2025. Third Quarter Highlights Third quarter revenue grew 5% to $11.12 billion. Third quarter GAAP diluted earnings per share (EPS) was $4.27, in-line with the prior-year quarter. Third quarter adjusted EPS grew 10% to $5.79. Delivered excellent operational performance... Read more
SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended September 30, 2025. Q3 Highlights Worldwide procedures (da Vinci and Ion combined) grew approximately 20% compared with the third quarter of 2024. Da Vinci procedures grew approximately 19% and Ion procedures grew a... Read more
WASHINGTON, Oct. 21, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 26, 2025. Key Third Quarter 2025 Results Net earnings were $908 million, or $1.27 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.89. Revenues increased 4.5% year-over-year to $6.1 billion and non-GAAP core revenue increased 3.0% year-over-year. Operating cash flow was... Read more
FRANKLIN LAKES, N.J., Oct. 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, introduces the BD Incada™ Connected Care Platform, a new scalable, AI-enabled, cloud-based platform that unifies BD device data into one intelligent ecosystem for the first time. The BD Incada™ Platform is available now with the launch of the next-generation BD Pyxis™ Pro Automated Medication Dispensing Solution, creating... Read more
Acquisition to expand the neuromodulation offerings for people living with chronic pain MARLBOROUGH, Mass., Oct. 17, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic pain. Boston Scientific has been a strategic... Read more
WALTHAM, Mass. / Oct 16, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s proven growth strategy through the use of artificial intelligence (AI) with OpenAI. This collaboration will help to improve the speed and success of drug development, enabling customers to get medicines to patients faster and more cost effectively. Working with OpenAI, Thermo Fisher... Read more
At ASHG, an early access customer from the London Health Sciences Center Research Institute will demonstrate the power of the 5-base genome for accelerating resolution of rare disease cases Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic inquiry, providing researchers with new tool for precision medicine breakthroughs SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the release of its novel 5-base solution,... Read more
Third-quarter reported sales growth of 6.9 percent; organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales1 Third-quarter GAAP diluted EPS of $0.94; adjusted diluted EPS of $1.30 Reported operating margin of 18.1 percent of sales; adjusted operating margin of 23.0 percent, which reflects a 40 basis point increase ABBOTT PARK, Ill., Oct. 15, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for... Read more
FRANKLIN LAKES, N.J., Oct. 9, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in the XTRACT™ Registry, a prospective, multi-center, single-arm, post-market registry study designed to evaluate the real-world performance of the Rotarex™ Catheter System in the treatment of patients with peripheral artery disease (PAD) lesions. The XTRACT™ Registry is... Read more
FDA-cleared software release enhances navigation and broadens access to advanced imaging for lung biopsy procedures SUNNYVALE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food & Drug Administration (FDA) has cleared software advancements for the Ion endoluminal system (Ion). Ion, Intuitive’s robotic-assisted... Read more
Gorilla® Pilon Fusion Plating System Introduced for Complex Ankle Fusions Phantom® TTC Trauma Nail Enhances Treatment Options for Complex Hindfoot Injuries WARSAW, Ind., Oct. 8, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Paragon 28, a wholly owned subsidiary, today announced the full commercial launch of two innovative solutions for complex foot and ankle trauma to offer surgeons advanced tools... Read more
